Drugs / 11C-Trimethoprim
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03424525 | Feb 2018 → Oct 2023 | bacterial infectious disease | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]trimethoprim | “[11C]trimethoprim ([11C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP.” PMID 41275068 ↗ Nov 2025 |
| Known as | [11C]TMP | “[11C]trimethoprim ([11C]TMP) is a positron emission tomography (PET) imaging isotopologue of TMP.” PMID 41275068 ↗ Nov 2025 |
| Action | Inhibit | “reversible inhibitor of the prokaryotic enzyme dihydrofolate reductase (DHFR)” PMID 41275068 ↗ Nov 2025 |
| Modality | Diagnostic / imaging agent | “[11C]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT).” NCT03424525 ↗ |